AllianceBernstein
CMPX icon

AllianceBernstein’s Compass Therapeutics CMPX Stock Holding History

AllianceBernstein’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$451K Hold
83,940
– – ﹤0.01% 2695
2025
Q4 		$451K Sell
83,940
-20,220
-19% -$93.4K ﹤0.01% 2705
2025
Q3 		$365K Sell
104,160
-12,510
-11% -$39.5K ﹤0.01% 2852
2025
Q2 		$303K Buy
116,670
+95,230
+444% +$196K ﹤0.01% 2906
2025
Q1 		$40.7K Hold
21,440
– – ﹤0.01% 3153
2024
Q4 		$31.1K Sell
21,440
-2,740
-11% -$4.55K ﹤0.01% 3204
2024
Q3 		$44.5K Hold
24,180
– – ﹤0.01% 3196
2024
Q2 		$24.2K Buy
24,180
+10,700
+79% +$15.6K ﹤0.01% 3219
2024
Q1 		$26.7K Hold
13,480
– – ﹤0.01% 3116
2023
Q4 		$21K Hold
13,480
– – ﹤0.01% 3170
2023
Q3 		$26.6K Buy
13,480
+2,220
+20% +$5.49K ﹤0.01% 3164
2023
Q2 		$35.8K Buy
+11,260
New +$35.4K ﹤0.01% 3144

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein's CMPX Position: Q1 2026 in Review

AllianceBernstein held its Compass Therapeutics (CMPX) position steady in Q1 2026 at 83,940 shares worth $451K. The position accounts for ﹤0.01% of the portfolio, ranked #2695.

AllianceBernstein first reported a position in CMPX in Q2 2023 and has held it in 12 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • AllianceBernstein held 83,940 shares of Compass Therapeutics worth $451K as of Q1 2026.
  • AllianceBernstein left its Compass Therapeutics share count unchanged in Q1 2026.
  • Compass Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2695 holding.
  • AllianceBernstein first reported a position in Compass Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.